Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Individual Patient Compassionate Use of Fedratinib

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03723148
Expanded Access Status : Available
First Posted : October 29, 2018
Last Update Posted : March 4, 2019
Sponsor:
Collaborator:
Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation
Information provided by (Responsible Party):
Celgene

Brief Summary:
This is an expanded access program (EAP) for eligible participants designed to provide access to Fedratinib.

Condition or disease Intervention/treatment
Myelofibrosis Drug: Oral Fedratinib

Detailed Description:
This program is being offered on a patient by patient basis and will require company, Institutional Review Board/Independent Ethics Committee and Single Patient IND approval.

Layout table for study information
Study Type : Expanded Access
Expanded Access Type : Individual Patients
  See clinical trials of the intervention/treatment in this expanded access record.
Official Title: Compassionate Use of Fedratinib for Patients Who Have Previously Received TG101348, SAR302503 or Fedratinib



Intervention Details:
  • Drug: Oral Fedratinib
    Oral fedratinib administered as directed by treating physician.
    Other Name: FEDR

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:

Subjects will be considered if they received TG101348, SAR302503 or Fedratinib as a participant on a clinical trial prior to 31 Jan 2018.

Exclusion Criteria:

Subject is eligible for enrollment in an ongoing clinical trial using Fedratinib or has been treated with Fedratinib after 31 Jan 2018.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03723148


Contacts
Layout table for location contacts
Contact: Celgene Medical Information 1-888-771-0141 medinfo@celgene.com

Locations
Layout table for location information
United States, New Jersey
Celgene
Summit, New Jersey, United States, 07901
Sponsors and Collaborators
Celgene
Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation

Layout table for additonal information
Responsible Party: Celgene
ClinicalTrials.gov Identifier: NCT03723148     History of Changes
Other Study ID Numbers: FEDR
First Posted: October 29, 2018    Key Record Dates
Last Update Posted: March 4, 2019
Last Verified: February 2019

Keywords provided by Celgene:
Expanded Access
Compassionate Use

Additional relevant MeSH terms:
Layout table for MeSH terms
Primary Myelofibrosis
Myeloproliferative Disorders
Bone Marrow Diseases
Hematologic Diseases